04:24 PM EST, 11/14/2025 (MT Newswires) -- Biogen (BIIB) on Friday said it completed its acquisition of Alcyone Therapeutics, adding the company's ThecaFlex DRx implantable intrathecal delivery system to support future use with Spinraza, its spinal muscular atrophy treatment.

The device is designed to replace repeat lumbar punctures and is currently being studied in the PIERRE trials.

Biogen said it aims to introduce the system for Spinraza in 2028, subject to trial results and regulatory approvals.